Description
GMP Certificated Pharmaceutical NSI 189 Nootropic API Powder CAS 1270138-40-3
Description
| Cas: | 1270138-40-3 | MF: | C22H30N4O |
|---|---|---|---|
| MW: | 366.5 | Origin: | China |
| Sample: | Available | Appearance: | Powder |
| Storage: | Inert Atmosphere,Room Temperature | Boiling Point: | 534.7±50.0 °C(Predicted) |
| Density: | 1.134±0.06 G/cm3(Predicted) | Color: | White |
| High Light: |
GMP NSI 189 Nootropic, Pharmaceutical NSI 189 Nootropic, 1270138-40-3 NSI 189 Nootropic |
||
GMP Certificated Pharmaceutical Nsi-189 API Powder CAS 1270138-40-3 with Best Price
Product introduction
| Product name | Nsi-189 |
| CAS No. | 1270138-40-3 |
| MF | C22H30N4O |
| MW | 366.5 |
| Origin | China |
| Appearance | White powder |
| Sample | Available |
| Density | 1.134±0.06 g/cm3(Predicted) |
Description
NSI-189 is a nootropic and neurogenic research chemical derived from nicotinamide and pyrazine.IC50 value:Target: in vitro: NSI-189 has been shown to stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. The hippocampus is responsible for the consolidation of information from short-term memory to long-term memory, along with spatial navigation [1] [2].in vivo: NSI-189 has been shown to increase the hippocampal volume of healthy adult mice by 20%.
Benefits
Tests have shown that NSI-189 significantly improved behavioral responses that are associated with depression . In humans it may counter hippocampal atrophy which is seen in disorders such as MDD, reversing their symptoms. A phase 1B randomized, double-blind, placebo-controlled, multiple-dose escalation study conducted over a 28 day period showed behavioral efficacy in 24 patients who were orally administered NSI-189 . The efficacy measurements showed a clinically meaningful reduction in cognitive and depressive symptoms across all measures, and appeared to persist over time during follow up for the efficacy assessments which included the Clinical Global Impression – Improvement (CGI-I), Montgomery-Aserb Depression Rating Scale (MADRS), Cognitive and Physical Functioning Questionnaire (CPFQ, and the Symptoms of Depression Questionnaire (SDQ) .
